229 related articles for article (PubMed ID: 11724786)
1. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
[TBL] [Abstract][Full Text] [Related]
2. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
Kennedy K; Gigoux V; Escrieut C; Maigret B; Martinez J; Moroder L; Fréhel D; Gully D; Vaysse N; Fourmy D
J Biol Chem; 1997 Jan; 272(5):2920-6. PubMed ID: 9006937
[TBL] [Abstract][Full Text] [Related]
3. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin.
Gigoux V; Escrieut C; Fehrentz JA; Poirot S; Maigret B; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy D
J Biol Chem; 1999 Jul; 274(29):20457-64. PubMed ID: 10400673
[TBL] [Abstract][Full Text] [Related]
4. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
[TBL] [Abstract][Full Text] [Related]
5. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.
Archer-Lahlou E; Tikhonova I; Escrieut C; Dufresne M; Seva C; Pradayrol L; Moroder L; Maigret B; Fourmy D
J Med Chem; 2005 Jan; 48(1):180-91. PubMed ID: 15634012
[TBL] [Abstract][Full Text] [Related]
6. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies.
Galés C; Poirot M; Taillefer J; Maigret B; Martinez J; Moroder L; Escrieut C; Pradayrol L; Fourmy D; Silvente-Poirot S
Mol Pharmacol; 2003 May; 63(5):973-82. PubMed ID: 12695525
[TBL] [Abstract][Full Text] [Related]
7. The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.
Gouldson P; Legoux P; Carillon C; Delpech B; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 2000 Jul; 400(2-3):185-94. PubMed ID: 10988332
[TBL] [Abstract][Full Text] [Related]
8. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
9. Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state.
Gigoux V; Escrieut C; Silvente-Poirot S; Maigret B; Gouilleux L; Fehrentz JA; Gully D; Moroder L; Vaysse N; Fourmy D
J Biol Chem; 1998 Jun; 273(23):14380-6. PubMed ID: 9603948
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanism underlying partial and full agonism mediated by the human cholecystokinin-1 receptor.
Archer-Lahlou E; Escrieut C; Clerc P; Martinez J; Moroder L; Logsdon C; Kopin A; Seva C; Dufresne M; Pradayrol L; Maigret B; Fourmy D
J Biol Chem; 2005 Mar; 280(11):10664-74. PubMed ID: 15632187
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a direct interaction between the penultimate aspartic acid of cholecystokinin and histidine 207, located in the second extracellular loop of the cholecystokinin B receptor.
Silvente-Poirot S; Escrieut C; Galès C; Fehrentz JA; Escherich A; Wank SA; Martinez J; Moroder L; Maigret B; Bouisson M; Vaysse N; Fourmy D
J Biol Chem; 1999 Aug; 274(33):23191-7. PubMed ID: 10438490
[TBL] [Abstract][Full Text] [Related]
12. Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding.
Gouldson P; Legoux P; Carillon C; Delpech B; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 1999 Nov; 383(3):339-46. PubMed ID: 10594328
[TBL] [Abstract][Full Text] [Related]
13. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu.
Mills JS; Miettinen HM; Cummings D; Jesaitis AJ
J Biol Chem; 2000 Dec; 275(50):39012-7. PubMed ID: 10960471
[TBL] [Abstract][Full Text] [Related]
15. Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S.
Gouldson P; Legoux P; Carillon C; Dumont X; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 2000 Feb; 389(2-3):115-24. PubMed ID: 10688974
[TBL] [Abstract][Full Text] [Related]
16. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
[TBL] [Abstract][Full Text] [Related]
17. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
[TBL] [Abstract][Full Text] [Related]
18. Basic amino acids at the C-terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin-B receptors.
Wang HL
J Neurochem; 1997 Apr; 68(4):1728-35. PubMed ID: 9084447
[TBL] [Abstract][Full Text] [Related]
19. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands.
Kopin AS; McBride EW; Quinn SM; Kolakowski LF; Beinborn M
J Biol Chem; 1995 Mar; 270(10):5019-23. PubMed ID: 7890609
[TBL] [Abstract][Full Text] [Related]
20. A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin.
Silvente-Poirot S; Wank SA
J Biol Chem; 1996 Jun; 271(25):14698-706. PubMed ID: 8663021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
